CRBP SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Corbus Pharmaceuticals Corporate Presentation Outlines Pipeline Milestones and Financial Position

Oct 15, 2026

8-K

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Sep 14, 2026

8-K

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides Corporate Update

Aug 6, 2026

8-K

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

Jul 6, 2026

8-K

Corbus Pharmaceuticals Reports Positive Phase 1/2 Clinical Data for CRB-701 in Oropharyngeal and Cervical Cancers

May 26, 2026

8-K

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer and Announces Upcoming CRB-701 Data Conference Call

May 21, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* August 2026 ATM | Offering amount: $127,500,000 | Bank: Jefferies LLC

Aug 7, 2026

424B3

OFFERING - OTHER | Offering amount: $300,000,000

Mar 25, 2026

424B5

REGISTERED OFFERING

Nov 3, 2025

424B5

PENDING FIXED PRICE OFFERING | Bank: Jefferies, Piper Sandler

Oct 30, 2025

424B3

UPDATED | ATM | Offering amount: $150,000,000.00

Mar 20, 2024

424B5

SHELF OFFERING | Shares amount: 4,325,000 | Share price: $19.00 | Offering amount: $82,175,000.00

Feb 1, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 17, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 29, 2026

S-3

March 2026 SHELF

Mar 11, 2026

S-8

Registration

May 31, 2024

S-3

SHELF | ATM | Offering amount: $300,000,000.00 EFFECTIVE

Mar 13, 2024

S-3MEF

Registration

Jan 31, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 16, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 2, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 2, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 1, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 1, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 10, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Cormorant Asset Management, LP (Reporting)

Nov 2, 2026

SCHEDULE 13G/A

Cormorant Asset Management, LP (Filed by)

Nov 2, 2026

SCHEDULE 13G/A

Aberdeen Group plc (Filed by)

Oct 29, 2026

SCHEDULE 13G

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Sep 30, 2026

Ben Yong (Reporting)

Sep 15, 2026

Nicacio Leonardo Viana (Reporting)

Aug 17, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 23, 2026

CORRESP

Form CORRESP - Correspondence

Mar 18, 2026

LETTER

Form UPLOAD - SEC-generated letter

Mar 13, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 21, 2024

CORRESP

Form CORRESP - Correspondence

Mar 18, 2024

LETTER

Form UPLOAD - SEC-generated letter

Mar 15, 2024

Corbus Pharmaceuticals Holdings, Inc. CRBP · SEC Filings